In this episode, we dive into the latest advancements in Alzheimer’s disease (AD) biomarkers, focusing on the diagnostic and predictive potential of plasma p-tau217.

As an alternative to traditional PET assessment, blood-based biomarker detection has the potential to provide a time-efficient, cost-effective strategy for pre-screening and treatment monitoring in AD clinical trials. Although the widespread use of blood-based biomarkers in clinical practice remains to be seen, they also hold promise in expediting diagnostic/prognostic procedures for AD.

We are joined by renowned researchers who discuss their work to test and validate p-tau217, both as a tool for clinical trials and for use in daily practice. 

With Marco Bucci, PhD, Karolinska Institutet, Stockholm, Sweden; Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO; Pamela Lukasewicz Ferreira, PhD, University of Pittsburgh, Pittsburgh, PA; and Lyduine Collij, PhD, Lund University, Lund, Sweden.

The post Exploring plasma p-tau217: a game-changer in Alzheimer’s trials appeared first on VJDementia.